About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a company based in Boston (United States) founded in 2004 was acquired by OticPharma in September 2016.. Tokai Pharmaceuticals has raised $161 million across 6 funding rounds from investors including OticPharma, Apple Tree Partners and Novartis Venture Fund. The company has 17 employees as of December 31, 2022. Tokai Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Boston, United States
- Employees 17 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
$-45.09 M-94as on Dec 31, 2015
-
EBITDA
$-45.26 M-93as on Dec 31, 2015
-
Total Equity Funding
$161 M (USD)
in 6 rounds
-
Latest Funding Round
$35.5 M (USD), Series E
May 15, 2013
-
Investors
OticPharma
& 2 more
-
Employee Count
17
as on Dec 31, 2022
-
Acquired by
OticPharma
(Sep 01, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Tokai Pharmaceuticals
Tokai Pharmaceuticals has successfully raised a total of $161M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $35.5 million completed in May 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series E — $35.5M
-
First Round
First Round
(08 May 2009)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2013 | Amount | Series E - Tokai Pharmaceuticals | Valuation |
investors |
|
| May, 2013 | Amount | Series E - Tokai Pharmaceuticals | Valuation |
investors |
|
| Sep, 2011 | Amount | Series D - Tokai Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tokai Pharmaceuticals
Tokai Pharmaceuticals has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include OticPharma, Apple Tree Partners and Novartis Venture Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location | |
|
Therapeutic products for ENT disorders are developed via FoamOtic technology.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tokai Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Tokai Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tokai Pharmaceuticals Comparisons
Competitors of Tokai Pharmaceuticals
Tokai Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Tokai Pharmaceuticals
When was Tokai Pharmaceuticals founded?
Tokai Pharmaceuticals was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Where is Tokai Pharmaceuticals located?
Tokai Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Tokai Pharmaceuticals a funded company?
Tokai Pharmaceuticals is a funded company, having raised a total of $161M across 6 funding rounds to date. The company's 1st funding round was a Series D of $23M, raised on May 08, 2009.
How many employees does Tokai Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Tokai Pharmaceuticals is 17.
What does Tokai Pharmaceuticals do?
Tokai Pharmaceuticals was founded in 2004 in Boston, United States, within the biotechnology sector. Focus is placed on developing oral small-molecule therapies for cancer patients, particularly those with metastatic, castration-resistant prostate cancer expressing the AR-V7 splice variant. The lead candidate, galeterone, is advanced under global development and commercial rights. Additional efforts involve identifying compounds to disrupt androgen receptor signaling via enhanced degradation. Operations center on oncology research and pipeline expansion.
Who are the top competitors of Tokai Pharmaceuticals?
Tokai Pharmaceuticals's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Tokai Pharmaceuticals's investors?
Tokai Pharmaceuticals has 3 investors. Key investors include OticPharma, Apple Tree Partners, and Novartis Venture Fund.